作者
Abhishek Abhishek, Rosemary J Boyton, Nicholas Peckham, Áine McKnight, Laura C Coates, James Bluett, Vicki Barber, Lucy Cureton, Anne Francis, Duncan Appelbe, Lucy Eldridge, Patrick Julier, Ana M Valdes, Tim Brooks, Ines Rombach, Daniel M Altmann, Jonathan S Nguyen-Van-Tam, Hywel C Williams, Jonathan A Cook, Ira Pande, Ting Seng Tang, Gui Tran, Alison Layton, Elizabeth Price, Lindsay Whittam, Srinivasan Venkatachalam, Ashley Hawarden, Gwenan Huws, Arthur Pratt, Nick J Reynolds, David Walsh, Theresa Joseph, Rengi Mathew, Stamatios Oikonomou, Catherine Gwynne, Rory Crowder, Vadivelu Saravanan, Alaa Mustafa, Cristina Tacu, Thomas Batty, Emmanuel George, Anushka Soni, Sarah Horton, Ayesha Madan, Karl Gaffney, Agnieszka Lapin, Sarah Bingham, Nick Levell, Edwin Lim, Nicola Gullick, Chris Holroyd, Salema Khalid, May Lwin, Mike Green, Laura Hunt, Nicola Alcorn, Rob Ellis, Samantha Hider, Alaa Hassan, Taryn Youngstein, Karen Douglas, Gen Nen Ho, Kirsty Levasseur, Sara Treacy, Myrto Cheila, John Pradeep, Ceril Rhys-Dillon, Catrin Jones
发表日期
2022/9/1
期刊
The Lancet Respiratory Medicine
卷号
10
期号
9
页码范围
840-850
出版商
Elsevier
简介
Background
Immunosuppressive treatments inhibit vaccine-induced immunity against SARS-CoV-2. We evaluated whether a 2-week interruption of methotrexate treatment immediately after the COVID-19 vaccine booster improved antibody responses against the S1 receptor-binding domain (S1-RBD) of the SARS-CoV-2 spike protein compared with uninterrupted treatment in patients with immune-mediated inflammatory diseases.
Methods
We did an open-label, prospective, two-arm, parallel-group, multicentre, randomised, controlled, superiority trial in 26 hospitals in the UK. We recruited adults from rheumatology and dermatology clinics who had been diagnosed with an immune-mediated inflammatory disease (eg, rheumatoid arthritis, psoriasis with or without arthritis, axial spondyloarthritis, atopic dermatitis, polymyalgia rheumatica, and systemic lupus erythematosus) and who were taking low-dose weekly …
引用总数